Couverture de 198. Addiction, Inc. with Emily Dufton

198. Addiction, Inc. with Emily Dufton

198. Addiction, Inc. with Emily Dufton

Écouter gratuitement

Voir les détails

À propos de ce contenu audio

Emily Dufton joins me to talk about how the death of her high school friend after 15 years of escalating opioid use led her on a journey to uncover the origins of the American opioid crisis and our failure to treat patients. She traces those roots back to the well‑intentioned but misguided efforts of the Nixon Administration in the 1970s, the punitive turn of the Reagan‑era War on Drugs, and the policies that followed. Emily also connects these policy choices to the rise of pharmaceutical profiteering—from Purdue Pharma, the maker of OxyContin, to other drug manufacturers who have collectively paid more than $60 billion in fines and civil penalties for practices that, in many ways, helped start the fire and then attempted to sell the hose.

To read Emily’s book, Addiction, Inc.:

Addiction, Inc.: Medication-Assisted Treatment and America’s Forgotten War on Drugs, Dufton

Contact me at silverliningshandbookpod@gmail.com

Check out the Silver Linings Handbook website at:

https://silverliningshandbook.com/

Check out our Patreon to support the show at:

https://www.patreon.com/thesilverliningshandbook

Join our Facebook Group at:

https://www.facebook.com/groups/1361159947820623

Visit the Silver Linings Handbook store to support the podcast at:

https://www.bonfire.com/store/the-silver-linings-handbook-podcast-store

Visit The True Crime Times Substack at:

https://truecrimemessenger.substack.com

The Silver Linings Handbook podcast is a part of the ART19 network. ART19 is a subsidiary of Wondery and Amazon Music.

See the Privacy Policy at https://art19.com/privacy and the California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

adbl_web_anon_alc_button_suppression_c
Aucun commentaire pour le moment